journal
MENU ▼
Read by QxMD icon Read
search

Nature Reviews. Clinical Oncology

journal
https://www.readbyqxmd.com/read/30420734/addendum-low-value-approvals-and-high-prices-might-incentivize-ineffective-drug-development
#1
Vinay Prasad, Christopher McCabe, Sham Mailankody
In hindsight, we realize that we could have been more precise when using the terms 'profit' and 'revenue' in our article 'Low-value approvals and high prices might incentivize ineffective drug development'. Total revenue is defined as the receipts from sales1 . Profit is defined as the excess of the receipts from sales over the spending of a business during any period1 . Hence, profit is the total revenue minus the costs of a business, over a given period. Profit calculations include credit transactions and asset revaluations as well as cash transactions and changes in the value of real assets1 ...
November 12, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30413793/active-surveillance-for-prostate-and-thyroid-cancers-evolution-in-clinical-paradigms-and-lessons-learned
#2
REVIEW
Lisa M Lowenstein, Spyridon P Basourakos, Michelle D Williams, Patricia Troncoso, Justin R Gregg, Timothy C Thompson, Jeri Kim
The adverse effects of overdiagnosis and overtreatment observed in men with clinically insignificant prostate cancers after the introduction of prostate-specific antigen-based screening are now being observed in those with thyroid cancer, owing to the introduction of new imaging technologies. Thus, the evolving paradigm of active surveillance in prostate and thyroid cancers might be valuable in informing the development of future active surveillance protocols. The lessons learned from active surveillance and their implications include the need to minimize the use of broad, population-based screening programmes that do not incorporate patient education and the need for individualized or shared decision-making, which can decrease the extent of overtreatment...
November 9, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30410080/olaparib-maintenance-moves-to-first-line
#3
Peter Sidaway
No abstract text is available yet for this article.
November 8, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30410079/new-window-of-opportunity-with-icis-in-melanoma
#4
David Killock
No abstract text is available yet for this article.
November 8, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30401936/time-to-abandon-single-site-irradiation-for-inducing-abscopal-effects
#5
REVIEW
Eric D Brooks, Joe Y Chang
Considerable interest is being directed toward combining immune-checkpoint inhibition (ICI) with radiotherapy to improve response rates to ICI, which have been disappointingly low at around 15-30% among patients with advanced-stage cancers other than melanoma. Since a case report published in 2012, in which authors described the resolution of metastatic disease after irradiation of a single lesion in a patient who had been receiving ICI, hundreds of clinical trials have been launched with the aim of testing the safety and/or efficacy of radiotherapy in combination with immunotherapy, nearly all of which use this single-site irradiation, or 'abscopal', approach...
November 6, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30401935/benefit-in-patients-with-pd-l1-positive-tnbc
#6
Diana Romero
No abstract text is available yet for this article.
November 6, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30401934/outcomes-depend-on-tumour-histology
#7
Diana Romero
No abstract text is available yet for this article.
November 6, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30401933/interferon-enhances-immune-checkpoint-inhibition
#8
Diana Romero
No abstract text is available yet for this article.
November 6, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30401932/benefit-with-vr-cap-in-mantle-cell-lymphoma
#9
Diana Romero
No abstract text is available yet for this article.
November 6, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30397331/survival-data-from-paloma-3-reported
#10
Peter Sidaway
No abstract text is available yet for this article.
November 5, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30390038/neuroendocrine-neoplasia-goes-molecular-time-for-a-change
#11
Guido Rindi, Bertram Wiedenmann
No abstract text is available yet for this article.
November 2, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30385811/long-term-benefits-in-combi-ad
#12
David Killock
No abstract text is available yet for this article.
November 1, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30367139/fibroblast-growth-factor-receptors-as-treatment-targets-in-clinical-oncology
#13
REVIEW
Masaru Katoh
FGFRs are receptor tyrosine kinases with a role in several biological processes, such as the regulation of development and tissue repair. However, alterations in FGFRs 1-4, such as amplifications, fusions and mutations, as well as aberrant epigenetic or transcriptional regulation and changes in tumour-stromal interactions in the tumour microenvironment, can lead to the development and/or progression of cancer. Similar to other kinase alterations, such alterations are targetable using small molecules or antibodies, and the benefits of FGFR inhibitors have been demonstrated in clinical trials involving subsets of patients with solid tumours harbouring FGFR alterations...
October 26, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30361681/hyperprogressive-disease-recognizing-a-novel-pattern-to-improve-patient-management
#14
REVIEW
Stéphane Champiat, Roberto Ferrara, Christophe Massard, Benjamin Besse, Aurélien Marabelle, Jean-Charles Soria, Charles Ferté
Anti-PD-1/PD-L1 monoclonal antibodies have substantially improved the overall survival of a subset of patients across multiple solid tumour types, but other patients can have a deterioration of their disease as a result of such therapies. This paradoxical phenomenon is defined as hyperprogression. In this Review, we present the available evidence of hyperprogressive disease following immune-checkpoint inhibition, the pathophysiological hypotheses that might explain hyperprogressive disease and the current challenges for patient management in routine clinical settings...
October 25, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30356138/state-of-the-art-strategies-for-targeting-the-dna-damage-response-in-cancer
#15
REVIEW
Patrick G Pilié, Chad Tang, Gordon B Mills, Timothy A Yap
Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA damage response (DDR) and/or increased replication stress. These alterations promote the clonal evolution of cancer cells via the accumulation of driver aberrations, including gene copy-number changes, rearrangements and mutations; however, these same defects also create vulnerabilities that are relatively specific to cancer cells, which could potentially be exploited to increase the therapeutic index of anticancer treatments and thereby improve patient outcomes...
October 24, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30353109/bcc-identity-switch-breaks-restraints-of-hedgehog-pathway-inhibition
#16
David Killock
No abstract text is available yet for this article.
October 23, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30341417/optimizing-the-outcomes-of-pancreatic-cancer-surgery
#17
REVIEW
Oliver Strobel, John Neoptolemos, Dirk Jäger, Markus W Büchler
Pancreatic cancer is likely to become the second most frequent cause of cancer-associated mortality within the next decade. Surgical resection with adjuvant systemic chemotherapy currently provides the only chance of long-term survival. However, only 10-20% of patients with pancreatic cancer are diagnosed with localized, surgically resectable disease. The majority of patients present with metastatic disease and are not candidates for surgery, while surgery remains underused even in those with resectable disease owing to historical concerns regarding safety and efficacy...
October 19, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30333516/ntrk-fusion-positive-cancers-and-trk-inhibitor-therapy
#18
REVIEW
Emiliano Cocco, Maurizio Scaltriti, Alexander Drilon
NTRK gene fusions involving either NTRK1, NTRK2 or NTRK3 (encoding the neurotrophin receptors TRKA, TRKB and TRKC, respectively) are oncogenic drivers of various adult and paediatric tumour types. These fusions can be detected in the clinic using a variety of methods, including tumour DNA and RNA sequencing and plasma cell-free DNA profiling. The treatment of patients with NTRK fusion-positive cancers with a first-generation TRK inhibitor, such as larotrectinib or entrectinib, is associated with high response rates (>75%), regardless of tumour histology...
October 17, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30317250/the-promise-of-escat-a-new-system-for-evaluating-cancer-drug-target-pairs
#19
Bishal Gyawali, Aaron S Kesselheim
No abstract text is available yet for this article.
October 13, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/30291292/a-balancing-act-dual-immune-checkpoint-inhibition-for-oesophagogastric-cancer
#20
Kazuto Harada, Ahmed A F Abdelhakeem, Jaffer A Ajani
No abstract text is available yet for this article.
October 5, 2018: Nature Reviews. Clinical Oncology
journal
journal
20200
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"